March 2022

Sleep Disorders and Autonomic Nervous System Dysfunction

iRBD, Pre-PD /

Parasympathetic nervous system activity dominates during non-rapid eye movement (REM) sleep, whereas the sympathetic nervous system is dominant during REM sleep. The balance between the sympathetic and parasympathetic nervous systems reduces the heart rate and blood pressure during non-REM sleep and increases these parameters during REM sleep and wakefulness. Heart rate variability analysis, a non-invasive […]

Sleep Disorders and Autonomic Nervous System Dysfunction Read More »

Exploiting Caenorhabditis elegans to discover human gut microbiota-mediated intervention strategies in protein conformational diseases

A-Synuclein, Biomarkers, Butyrate, Gut Dysbiosis, Probiotics, Prebiotics and Symbiotics /

Age-dependent protein-conformational diseases (PCDs), such as Alzheimer’s disease (AD), Parkinson’s disease (PD), or amyotrophic lateral sclerosis (ALS), are characterized by misfolding and aggregation of metastable proteins present within the proteome of the affected individual. Recent evidence supports the notion that bacteria and bacterial products may be affecting the stability of these culprit host proteins and

Exploiting Caenorhabditis elegans to discover human gut microbiota-mediated intervention strategies in protein conformational diseases Read More »

Predictors of RBD progression and conversion to synucleinopathies

Biomarkers, iRBD /

There is a variety of potential biomarkers for monitoring disease progression and predicting iRBD conversion into synucleinopathies. A combined multimodal biomarker model could offer a more sensitive and specific tool. Further longitudinal studies are warranted to iRBD as a high-risk population for early neuroprotective interventions and disease-modifying therapies. CLICK TO REVIEW

Predictors of RBD progression and conversion to synucleinopathies Read More »

ORAL BUTYRATE AND MICROBIOTA-TARGETED TREATMENTS FOR PARKINSON’S
DISEASE: EFFICACY STUDIES IN TRANSGENIC MICE.

A-Synuclein, Biomarkers, Butyrate, Gut Microbiota, Gut-Brain axis, Pre-PD, Probiotics, Prebiotics and Symbiotics /

Current pharmacological treatments for Parkinson’s disease (PD) provide relief for motorsymptoms but fail to alleviate prevalent non-motor symptoms (NMS)- such as gastrointestinal(GI) dysfunction which often occurs before the development of motor symptoms. Strategies toslow the progression of PD have been proposed, but so far none has proven successful. PDpatients display changes in gut microbiome composition

ORAL BUTYRATE AND MICROBIOTA-TARGETED TREATMENTS FOR PARKINSON’S
DISEASE: EFFICACY STUDIES IN TRANSGENIC MICE. Read More »

Probiotic Bacillus subtilis
Protects against a-Synuclein
Aggregation in C. elegans

A-Synuclein, Butyrate, Gut Dysbiosis, Probiotics, Prebiotics and Symbiotics /

Recent discoveries have implicated the gut microbiome in the progression and severity of Parkinson’s disease; however, how gut bacteria affect such neurodegenerative disorders remains unclear. Here, we report that the Bacillus subtilis probiotic strain PXN21 inhibits a-synuclein aggregation and clears preformed aggregates in an established Caenorhabditis elegans model of synucleinopathy. This protection is seen in

Probiotic Bacillus subtilis
Protects against a-Synuclein
Aggregation in C. elegans Read More »

The effects of the Green-Mediterranean diet on cardiometabolic health are linked to gut microbiome modifications: a randomized controlled trial

Diet and Exercise, Gut Dysbiosis, Gut Microbiota, Pre-PD, Probiotics, Prebiotics and Symbiotics /

Our findings support a mediating role of the gut microbiome in the beneficial effects of the Green-MED diet enriched with Mankai and green tea on cardiometabolic risk factors. CLICK TO REVIEW

The effects of the Green-Mediterranean diet on cardiometabolic health are linked to gut microbiome modifications: a randomized controlled trial Read More »

Impact of Probiotic and Prebiotic on Gut Microbiota in Pre-diabetes and Type 2 Diabetes

Gut Microbiota, Gut-Brain axis, Parkinson's Disease, Pre-PD, Probiotics, Prebiotics and Symbiotics, Short Chain Fatty Acids /

The increased worldwide prevalence of pre-diabetes and diabetes, especially type 2 diabetes, requiring different strategies for their prevention and management. A new focus is the reversal of diabetes dysbiosis, a disruption of gut microbiota homeostasis, which is closely related to elevated blood glucose levels and altered metabolic parameters. In this sense, a balanced diet plays a key role, and,

Impact of Probiotic and Prebiotic on Gut Microbiota in Pre-diabetes and Type 2 Diabetes Read More »

Gut Microbiota Dysbiosis: Triggers, Consequences, Diagnostic and Therapeutic Options

Butyrate, Fecal Transplants (FMT), Gut Dysbiosis, Gut Microbiota, Probiotics, Prebiotics and Symbiotics, Short Chain Fatty Acids /

The global incidence of numerous immune-mediated, metabolic, neurodegenerative, and psychiatric diseases is steadily increasing [1,2,3]. The increased morbidity of human populations makes them more vulnerable to additional burdens, including infectious diseases. For example, the mortality rate of diabetics infected with the original variant of the SARS Co-2 virus was about twice that of the general

Gut Microbiota Dysbiosis: Triggers, Consequences, Diagnostic and Therapeutic Options Read More »

Inflammation and immune dysfunction in Parkinson disease

Gut Microbiota, Parkinson's Disease, Pre-PD /

Parkinson disease (PD) is a progressive neurodegenerative disease that affects peripheral organs as well as the central nervous system and involves a fundamental role of neuroinflammation in its pathophysiology. Neurohistological and neuroimaging studies support the presence of ongoing and end-stage neuroinflammatory processes in PD. Moreover, numerous studies of peripheral blood and cerebrospinal fluid from patients

Inflammation and immune dysfunction in Parkinson disease Read More »

Microbiota and the gut-brain-axis: Implications for new therapeutic design in the CNS

Gut Microbiota, Gut-Brain axis /

The recent revelation that the gut microbiome, home to approximately 100 trillion microorganisms, is implicated in the development of both health and disease has spurred an exponential increase in interdisciplinary research involving gut microbiology. In all this hype, there is a need to better understand and contextualize the emerging evidence for the role of the gut microbiota in

Microbiota and the gut-brain-axis: Implications for new therapeutic design in the CNS Read More »